About the Project
Project Summary: Invasive infections by Mucorales fungi are life-threatening complications of severe blast trauma. Mucorales are resistant to most antifungals and cause devastating infections, yet are poorly understood. Mucorales are soil-swelling fungi and can host endosymbiotic bacteria that can influence fungal pathogenicity. We showed that removing endosymbionts can reduce fungal fitness. This project will identify compounds that target this partnership as an Achilles Heel as a strategy to mitigating fungal infections.
About the Project: Combat-related invasive fungal infections are life-threatening complications of severe blast trauma1. They are often caused by soil-dwelling Mucorales fungi with high-level resistance to most currently available antifungal drugs. Yet devastating mucormycosis is understudied and poorly understood.
Mucorales infections can be polymicrobial: approximately 40% of clinical isolates host bacteria that can be either transiently associated or form obligate holobionts. Our unbiased survey of clinical Mucorales isolates found much more diversity than previously reported. The pairings can encompass a surprising variety of both fungal hosts and bacterial partners, spanning Mucorales genera and both gram positive and negative species. Importantly, our data demonstrate bacteria can mediate fungal virulence by 1) increasing fungal stress resistance and 2) secreting factors that block host responses2. Recent clinical reports also suggest Mucorales may be infection reservoirs for bacteremia in vivo3,4. Disrupting holobionts can reduce fungal fitness2. Together, these findings suggest that compounds that disrupt holobionts may offer an important opportunity for controlling and mitigating fungal infections. Finally, our work swapping fungal host and bacterial partner reveal growth of non-host fungi can be controlled by bacterial secreted factors. This suggests such bacteria may represent an untapped source of antifungal compounds.
This project will identify inhibitors of Mucorales-bacterial interactions underpinning virulence, and fill a major gap in knowledge around biologically relevant secreted products. The student will:
1) Perform HTP screens to disrupt holobionts using panels of well-characterised chemical fragments, FDA approved and in-pipeline drugs.
2) Perform HTP screens for antimicrobial activity using a library of secreted factors generated from fungal isolates.
3) Prioritize and characterise hits and their modes of action.
Aim 1) Using whole cell screening assays established at the MRC Centre for Medical Mycology, the student will perform a HTP screen for inhibitors of germination in two different Rhizopus holobionts. These representative clinical isolates are genetically tractable to enable downstream functional analyses. The aim serves as a training period for the student in HTP methodologies using well-characterised and stable libraries of compounds (Maybridge 500, Enamine) and will yield novel compounds that can block Mucorales growth.
Aim 2) Mucorales-bacterial interactions can elicit mutualistic or antagonistic outcomes, in part via uncharacterised secreted factors. These are often only produced under specific conditions, (i.e., in co-culture with other microbes). Using a panel of ~ 300 clinical and environmental holobionts and bacteria, the student will screen for inhibitors of microbial growth against a panel of clinically relevant category 2 and 3 fungi and bacteria. Supernatants with antimicrobial activity will be subjected to size exclusion chromotography and HPLC to identify active fractions, and then analysed by LC/MS for known molecules. Novel compounds will be passed on to collaborators for identification by NMR and structural methods, paired with bioinformatic data on gene expression profiles of the source species.
Aim 3) After elimination of pan-assay interference compounds (false-positives), chemicals with favourable potency, spectra of activity and toxicity profiles will be further characterized to rule out targets conserved in humans or that may threaten ecosystem integrity. Remaining compounds will be further characterized for possible modes of action, and analogous compounds sought from commercial suppliers and/or synthesized to seek structure activity relationships. The student will assess inhibitor impact and likely modes of actions on secondary phenotypes, (fungal growth; stress resistance; holobiont stability) and test for synergistic activity with established antifungals. Where a priori knowledge is absent, the student will mine locally available fungal mutant libraries for hyper- or hypo- susceptibility phenotypes.
3.1 Hits will be assessed for toxicity in collaboration with the Dstl. Here the student will receive training in a range of assays to investigate the toxicity of any new compounds identified in Aim 3. These assays will include assessment of mitochondrial toxicity using Seahorse technology, measurement of lactate dehydrogenase and (dependent on the compounds) assessment of immune correlates. In addition, there is the potential to evaluate these compounds in the wax moth Galleria mellonella.
3.2 Working with partners at the Medicines Discovery Institute at Cardiff University, hits will be further characterised to assess drug-like properties. This will comprise predictions of physicochemical properties (including logP/D, PSA) to predict solubility, permeability and absorption [ChemAxon software suite] and predictions of potential metabolism [Stardop software] as well as measuring kinetic solubility and microsomal turnover (mouse/rat/human). Depending on the number of hits obtained, they will also be ranked and/or clustered to aid onward prioritization.
Supervisors
Lead Supervisor: Dr Elizabeth Ballou, University of Exeter, Faculty of Health and Life Sciences
Co-Supervisor: Dr Dora Corzo-Leon, University of Exeter, Faculty of Health and Life Sciences
Co-Supervisor: Professor Sarah Harding, DSTL, Porton Down
Co-Supervisor: Professor Simon Ward, Cardiff University, College of Biomedical and Life Sciences – Medicine Discovery Institute
Advertise from: Wednesday 17th May 2023
Closing date: Friday 16th June 2023
Who are the GW4 BioMed MRC DTP?
Funded by the Medical Research Council (MRC), the partnership brings together the Universities of Bath, Bristol, Cardiff (lead) and Exeter to develop the next generation of biomedical researchers. Students will have access to the combined research strengths, training expertise and resources of the four research-intensive universities, with opportunities to participate in interdisciplinary and ‘team science’. The DTP already has over 90 studentships over 6 cohorts in its first phase., along with 20 students in its second phase.
From its launch in 2016, our partnership aims to develop the next generation of medical researchers by offering to both medical and non-medical students across three strategic research themes.
• Infection, Immunity, Antimicrobial Resistance and Repair
• Neuroscience and Mental Health
• Population Health Sciences
Our portfolio of PhD projects reflects the collective strengths of the DTP: quantitative skills (including mathematical modelling), using data for discovery, in vivo skills, and interdisciplinary training and approaches.
Students in the GW4 BioMed2 MRC DTP have access to a broad range of training opportunities across all four universities. In addition, we provide bespoke training specific to students within the DTP, that spans the three strands of our training programme including research skills, professional and career development skills and opportunities to broaden horizons. Events throughout the programme will develop researcher communities across the partnerships.
Each BioMed2 studentship provides funding for 4 years, which includes a 3-month initial preparation period and a 3-month placement.
Entry requirements
Eligibility
• This studentship is open to applications from candidates who would be classified as UK citizens only.
• All studentships are competitively awarded.
• Applicants must have obtained, or be about to obtain, a UK degree, or the equivalent qualification gained outside the UK, in an appropriate area of medical sciences.
• The DTP also welcomes students from non-medical backgrounds, especially in areas of computing, mathematics, and the physical sciences.
• Academic qualifications are considered alongside any significant relevant non-academic experience.
• If English is not your first language, you will need to meet the English language requirements of the university that will host your PhD by the start of the programme, Please refer to the Exeter University website here for further information on this.
Funding Notes
This GW4 BioMed2 MRC DTP iCASE studentship includes full tuition fees at UK level only, stipend at the minimum UKRI rate plus an iCASE stipend top up contribution of £2,500 per year from DSTL, a Research & Training Support Grant (RTSG) valued between £2-5k per year and a £300 annual travel and conference grant based on a 4-year, full-time studentship.
Throughout the duration of the studentship, there will be opportunities to apply to the Flexible Funding Supplement for additional support to engage in high-cost training opportunities.
How to apply
How to apply and additional information
Please submit an application to the GW4 BioMed2 MRC DTP for an offer of funding – further details and a link to the online application form are available on our website https://gw4biomed.ac.uk/how-to-apply-for-students/ . The closing date for application is Friday 16th June 2023 at 5pm.







Reviews
There are no reviews yet.